Similar articles

• Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.

  Bechstein WO, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Ericzon BG, Bismuth H. Bechstein WO, et al. Transplant Proc. 1996 Apr;28(2):1008-10. Transplant Proc. 1996. PMID: 8623211 Clinical Trial. No abstract available.
• Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.

  Yussim A, Shaharabani E, Mor E, Lustig S, Bar-Nathan N, Shmueli D, Sobolev V, Dorfman B, Or H, Shapira Z. Yussim A, et al. Transplant Proc. 1996 Dec;28(6):3178-9. Transplant Proc. 1996. PMID: 8962233 No abstract available.
• Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.

  Platz KP, Tullius SG, Mueller AR, Schumacher G, Nüssler N, Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P. Platz KP, et al. Transplant Proc. 1996 Dec;28(6):3183-4. Transplant Proc. 1996. PMID: 8962235 No abstract available.
• Clinical use of FK 506 in liver transplantation.

  Klintmalm GB. Klintmalm GB. Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.
• Neoral is superior to FK 506 in liver transplantation.

  Levy GA. Levy GA. Transplant Proc. 1998 Aug;30(5):1812-5. doi: 10.1016/s0041-1345(98)00442-4. Transplant Proc. 1998. PMID: 9723293 Review. No abstract available.